COMMUNIQUÉS West-GlobeNewswire

Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
14/08/2025
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical Inc. , a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & [...]
Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements
14/08/2025
NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company at the forefront of the [...]
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by [...]
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
14/08/2025
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data [...]
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
14/08/2025
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial [...]
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
14/08/2025
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
14/08/2025
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic [...]
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
14/08/2025
Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation [...]
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
14/08/2025
Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential [...]
À l’occasion de la Journée mondiale du don d’organes, le KFSHRC annonce la réalisation de 10 greffes de reins croisées en 48 heures
14/08/2025
RIYAD, Arabie saoudite, 14 août 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) a réalisé avec succès 10 greffes de reins croisées en deux jours consécutifs, établissant ainsi le [...]
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
14/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
14/08/2025
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 [...]
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
14/08/2025
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux [...]
Kuros Biosciences Reports First Half of 2025 Results
14/08/2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 [...]
Zealand Pharma Announces Financial Results for the First Half of 2025
14/08/2025
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid [...]
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering
14/08/2025
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing [...]
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
13/08/2025
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, [...]
BioSig Technologies Inc. Announces Proposed Public Offering
13/08/2025
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention [...]
Applied Therapeutics Reports Second Quarter 2025 Financial Results
13/08/2025
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of [...]

Pages